Bgm (BGM) Non-Current Deffered Revenue (2019 - 2025)
Bgm (BGM) posted quarterly Non-Current Deffered Revenue of $240154.0 for Q3 2025, up 78.69% year-over-year from $134394.0 in Q3 2024, and up 0.96% quarter-over-quarter from $237869.0 in Q1 2025.
Bgm (BGM) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Bgm (BGM) has reported Non-Current Deffered Revenue for 7 consecutive years, with $240154.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Non-Current Deffered Revenue rose 78.69% year-over-year to $240154.0; the TTM figure through Sep 2025 stood at $240154.0 (up 78.69% YoY), while the FY2025 annual figure was $240154.0, up 78.69% from the prior year.
- Non-Current Deffered Revenue improved to $240154.0 in Q3 2025 per BGM's latest filing, from $237869.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $386.3 billion in Q1 2022 and bottomed at $134394.0 in Q3 2024.
- Historically, Non-Current Deffered Revenue has averaged $72.7 billion across 5 years, with a median of $240154.0 in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue plunged 100.0% — and 2025, when it soared 78.69%.
- Bgm's Non-Current Deffered Revenue stood at $403745.0 in 2021, then slipped by 23.23% to $309943.0 in 2022, then declined by 28.41% to $221879.0 in 2023, then tumbled by 39.43% to $134394.0 in 2024, then jumped by 78.69% to $240154.0 in 2025.
- Business Quant data shows BGM's Non-Current Deffered Revenue at $240154.0 in Q3 2025, $237869.0 in Q1 2025, and $134394.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Bgm | 29.71 Mn | 19.89 Mn | - | 240,154.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 240,154.00 |
| Mar 31, 2025 | 237,869.00 |
| Sep 30, 2024 | 134,394.00 |
| Mar 31, 2024 | 184,328.00 |
| Sep 30, 2023 | 221,879.00 |
| Mar 31, 2023 | 267.55 Bn |
| Sep 30, 2022 | 309,943.00 |
| Mar 31, 2022 | 386.34 Bn |
| Sep 30, 2021 | 403,745.00 |
| Sep 30, 2020 | 722,137.00 |
| Sep 30, 2019 | 972,338.00 |